News | December 06, 2022
Briefs: Natco Pharma & Lupin
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
